A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

December 9, 2015

Primary Completion Date

February 24, 2017

Study Completion Date

February 24, 2017

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

MEDI0382

MEDI0382 administered subcutaneously.

DRUG

Placebo

Placebo administered subcutaneously.

Trial Locations (11)

10117

Research Site, Berlin

23538

Research Site, Lübeck

24105

Research Site, Kiel

39120

Research Site, Magdeburg

41460

Research Site, Neuss

55116

Research Site, Mainz

68167

Research Site, Mannheim

81241

Research Site, München

89231

Research Site, Neu-Ulm

99084

Research Site, Erfurt

04103

Research Site, Leipzig

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MedImmune LLC

INDUSTRY